

DESCRIPTION

| | |
|---|---|
| Species Reactivity | Human |
| Specificity | Detects human EGFR with the aa 746-750 deletion in direct ELISAs and Western blots. |
| Source | Monoclonal Mouse IgG _{2A} Clone # 752502 |
| Purification | Protein A or G purified from hybridoma culture supernatant |
| Immunogen | Human EGFR synthetic peptide CPVAIKTSPKAN Accession # P00533 |
| Conjugate | Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm |
| Formulation | Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide |
| *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions. | |

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

| | |
|----------------------------|--|
| Western Blot | Optimal dilution of this antibody should be experimentally determined. |
| Immunocytochemistry | Optimal dilution of this antibody should be experimentally determined. |

PREPARATION AND STORAGE

| | |
|--------------------------------|---|
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied |

BACKGROUND

Epidermal growth factor receptor (EGFR, also known as ErbB1 and HER1) is the founding member of the ErbB family of receptor tyrosine kinases. Ligand binding induces receptor dimerization and autophosphorylation on multiple tyrosine residues. *EGFR* exon 19 deletions are in-frame deletions occurring within exon 19, which encodes part of the kinase domain. This mutation occurs with a frequency of approximately 48% in *EGFR* mutant lung tumors. It affects the catalytic domain (amino acids 746-750), and is predominantly associated with non-small cell lung cancer (1). In a metastatic setting, *EGFR* deletions like aa746-750 are predictors of efficacy of the *EGFR* tyrosine kinase inhibitors (1, 2).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.